Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular Assay.

Expert review of molecular diagnostics - 1 Jul 2006

Hasegawa Yoshinori, Ando Yuichi, Shimokata Kaoru

Abstract excerpt

Accumulating evidence provides support for the idea that determination of UGT1A1 polymorphisms before irinotecan (CPT-11) treatment is clinically useful and important for predicting and avoiding related toxicities. In 2005, the irinotecan label was updated in the USA in order to provide pharmacogenetic information. A dose reduction of irinotecan should be considered for patients known to be homozygous for the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Biological Assay

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Camptothecin

Share to Glucuronosyltransferase

Share to Homozygote

Share to Irinotecan

Share to Neoplasms

Share to Promoter Regions, Genetic

Source

Identifiers

PMID: 16824027
DOI: 10.1586/14737159.6.4.527

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular Assay.PMID 16824027Read ↗

Invader UGT1A1 molecular assay for irinotecan toxicity. A genetic test for an increased risk of toxicity from the cancer chemotherapy drug irinotecan (Camptosar).Semantic proximity Read ↗

Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time.Semantic proximity Read ↗

Pharmacogenetics and irinotecan therapy.Semantic proximity Read ↗

Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients.Semantic proximity Read ↗

Clinical Pharmacogenetics of Irinotecan (CPT-11)Semantic proximity Read ↗

UGT1A1 genotyping in patients undergoing treatment with irinotecan.Semantic proximity Read ↗

[UGT1A1 Genotyping for Proper Use of Irinotecan].Semantic proximity Read ↗

Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.Semantic proximity Read ↗

Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.Semantic proximity Read ↗

Genotyping of UGT1A1*80 as an Alternative to UGT1A1*28 Genotyping in SpainSemantic proximity Read ↗

Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapySemantic proximity Read ↗

UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.